NCT01890837已完成1 期
Effect of Daikenchuto (TU-100), a Gastrointestinal Nerve Modulator, on Rectal Sensation in Patients With Irritable Bowel Syndrome
Tsumura USA1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2013年8月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Sensation rating of urgency to defecate in response to 32 mmHg distension of rectum on a 100 mm VAS
研究概览
简要总结
The purpose of this study is to compare the effects of 5g of Daikenchuto (TU-100) three times per day (Daikenchuto [TU-100] is a botanical agent that modulates gastrointestinal nerves), and placebo on rectal sensation (sensation ratings of urgency to defecate and sensation threshold for pain) in response to rectal balloon distension by barostat in patients with IBS.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Meet Rome III criteria for IBS.
- •Willing and able to provide written informed consent.
- •If a female of childbearing potential, must be using an acceptable form of contraception during the study and for 30 days after the last dose. Acceptable methods include surgical sterilization, hormonal contraceptives (such as oral contraceptives, Depo-Provera, NuvaRing), condoms used with a spermicide, an IUD [Intrauterine device] or abstinence.
- •Females are not considered to be of childbearing potential if they are postmenopausal for at least 2 years or have been surgically sterilized.
- •Aged 18 to 65 years, inclusive.
- •Have a body mass index (BMI) between 18 and 40 kg/m2, inclusive.
- •Have a negative urine drug screening at Visit
- •Have normal or not clinically significant laboratory results as reviewed by the study physicians.
- •Have a normal rectal examination result on file within the past 2 years or performed at Visit 1 in order to exclude the possibility of an evacuation disorder (examination must exclude findings suggestive of an evacuation disorder such as high sphincter tone at rest, failure of perineal descent and spasm, tenderness or paradoxical contraction of the puborectalis muscles).
- •Agree to avoid alcohol during the entire study to avoid corrupting the data from the rectal barostat tests.
排除标准
- •Have a structural or metabolic diseases or conditions that affect the GI system.
- •Be taking any medication that in the opinion of the principal investigator has a potential to alter GI transit (this includes but is not limited to osmotic or stimulant laxatives, magnesium or aluminum-containing antacids, prokinetics, erythromycin, gabapentin, pregabalin, narcotics, anticholinergics, antidepressants [including selective norepinephrine reuptake inhibitors], antipsychotics, opiates, GABAergic agents and benzodiazepines).
- •Note: Tricyclic antidepressants are permissible at doses equal to or less than 25 mg daily; selective serotonin reuptake inhibitor antidepressants are permissible at low, stable doses. Analgesics such as Tylenol, ibuprofen, naproxen and aspirin are not permissible during Visits 2 and 3 to avoid corrupting data from the rectal barostat tests. All medications will be reviewed by the principal investigator on a case by case basis.
- •Rescue medications: Rescue medications will be reviewed and approved as necessary for exacerbation of constipation or diarrhea since the study medication treatment period is about 14 days total. The patient will contact the study staff to request review and approval of the use of a rescue medication by the principal investigator. The use of the rescue medication will be documented by the patient in the bowel pattern, bloating and pain diary. Rescue medications are not allowed within 7 days of the rectal sensation studies to ensure data integrity.
- •Have clinical evidence, including but not limited to, of a clinically significant abnormal physical examination or laboratory value or of a past event documented in the past medical record, or current clinically significant abnormal physical examination or laboratory value that could indicate significant cardiovascular, respiratory, renal, hepatic, GI, hematological, neurological, psychiatric or other diseases that interfere with the objectives of the study. If a laboratory test value falls outside of the reference range and is considered clinically significant, it may be repeated once at the discretion of the principal investigator. If the laboratory test result remains abnormal and clinically significant, the patient will be discontinued from the study and referred to a primary care physician for evaluation.
- •Be a known substance abuser or be considered to be an alcoholic not in remission.
- •Have participated in another clinical study in the past 30 days.
- •Have a history of allergic reactions to egg, ginseng, ginger or Sichuan pepper.
- •Be clinically lactose intolerant.
研究组 & 干预措施
Daikenchuto (TU-100) 15g/day
Experimental
Daikenchuto (TU-100) 5g TID/3 times per day (15g/day)
干预措施: Daikenchuto (TU-100) (Drug)
Placebo
Placebo Comparator
Placebo TID
干预措施: Placebo (Drug)
结局指标
主要结局
Sensation rating of urgency to defecate in response to 32 mmHg distension of rectum on a 100 mm VAS
时间窗: 14 days
Sensation threshold for pain in response to distention of the rectum
时间窗: 14 days
次要结局
- Rectal sensation thresholds (gas, urgency to defecate, first sensation)(14 days)
- IBS-QOL (Quality of Life) score(14 days)
- Ease of bowel movements(21 days)
- Completeness of evacuation(21 days)
- Stool frequency(21 days)
- Stool consistency as measured by the Bristol stool scale(21 days)
- Daily average severity of abdominal pain on 100mm VAS(21 days)
- Worst severity of abdominal pain each day measured on 100mm VAS scale(21 days)
- Daily average severity of bloating on 100mm VAS scale(21 days)
- Rectal sensation ratings (pain, gas) in response to 32 mmHg distension of the rectum(14 days)
- Rectal tone response to feeding 1,000 kcal meal(14 days)
- Rectal compliance at half-maximum pressure (Pr1/2)(14 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Effect of TU-100 on Rectal Compliance, Rectal Sensation and Small Bowel and Colonic Transit in Females With ConstipationGastric EmptyingWhole Gut TransitSmall Bowel TransitColonic TransitRectal ComplianceRectal SensationFunctional ConstipationNCT01139216Tsumura USA45
Unknown
2 期
Daikenchuto for Intestinal Dysmotility and Prevention of Postoperative Paralytic Ielus After PancreaticoduodenectomyParalytic IleusNCT01607307Wakayama Medical University220
已完成
1 期
Effect of TU-100 on Gastrointestinal and Colonic Transit in HumansPostoperative IleusNCT00871325Tsumura USA60
已完成
不适用
Clinical effectiveness of daikenchuto (TJ-100) on gastrointestinal symptom after colectomy in colorectal cancer patients with abdominal pain and distention due to a bowel movement disorder.Colorectal cancer patients with abdominal pain and distention due to a bowel movement disorder.JPRN-UMIN000008348Osaka Police Hospital32
终止
2 期
A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's DiseaseCrohn's DiseaseNCT01388933Tsumura USA79